Restylane / Bausch Health - LARVOL DELTA

P037 Efficacy and safety of injectable bio-revitalizers and rejuvenate therapies, including platelet-rich plasma and exosome-based treatments: a systematic review of licensed products in the UK. (PubMed, Br J Dermatol) - "Inclusion criteria focused on licensed products approved in the UK under MHRA and NICE regulations, such as Profhilo®, Restylane® Skinboosters, Sunekos®, Nucleofill®, Juvelook®, PRP and exosome-based therapies...This review offers a comprehensive evaluation of licensed bio-revitalizers and rejuvenate therapies, providing colleagues with evidence-based insights for improving patient care and advancing practice in aesthetic and therapeutic dermatology. The findings serve as a valuable teaching tool, fostering reflection on current practices and encouraging innovation within the field."

Journal • Review • Dermatology

A Prospective, Randomized, Active-Controlled, Evaluator-Blinded, Noninferiority Clinical Trial Examining a Non-Cross-Linked Bovine-Derived Type I/III Collagen Filler Combined with Hyaluronic Acid for Periocular Rejuvenation. (PubMed, Aesthetic Plast Surg) - "The combination of collagen and HA offers a comprehensive approach for periocular rejuvenation. This method combines the volumizing benefits of HA with the tissue-regenerative properties of collagen. Furthermore, this approach minimizes complications while enhancing treatment longevity, thus establishing a new standard for minimally invasive periocular rejuvenation."

Head-to-Head • Journal • Aesthetic Medicine

Clinical Durability of Hyaluronic Acid-Based Dermal Fillers for Facial Application: A Systematic Review. (PubMed, Aesthetic Plast Surg) - "HA filler longevity is influenced by manufacturing technology, tissue mobility, and anatomical factors. All technologies demonstrated good durability, though Vycross was associated with more long-term adverse events. Subjective satisfaction mirrored objective persistence, emphasizing the clinical relevance of both assessments. Individualized product selection remains essential to achieve safe, predictable, and satisfactory outcomes."

Journal • Review • Aesthetic Medicine

Safety and Effectiveness of 2 High-G Prime Soft Tissue Filler for Chin Augmentation: A Prospective, Randomized, Comparator-Controlled, Evaluator-Blinded Trial. (PubMed, Aesthet Surg J) - "With no statistically significant difference in overall volume utilized between HASHA and HAVLX, HASHA injections required 15.27% less volume in the menton/pognion to achieve visual correction. Additionally, HASHA demonstrated a significantly higher efficiency score for correction of nasomental angle. Secondary endpoints were not significantly different and demonstrate both products as being safe and effective."

Journal

An Expert Opinion on Hyaluronic Acid Fillers for Indian Facial Aesthetics: Insights From a Pre-meeting Questionnaire and Ad-Board Discussion. (PubMed, Cureus) - "Considering both anatomical changes and patient expectations, an individualized approach to facial aesthetic treatments is necessary. There is a need for Indian-specific aesthetic guidelines owing to limited published literature that respects cultural facial characteristics and evolving beauty standards across age groups."

Journal • Review • Aesthetic Medicine

Filler Up! Key Quality and Safety Considerations in Non-Cosmetic Applications of Soft-Tissue Fillers in Otolaryngology (AAO-HNSF 2025) - "Starting in 2003 with Restylane, hyaluronic acid (HA) fillers led the way, sparking a wave of innovation that now includes over 20 FDA-approved formulations for aesthetic use. Beyond hyaluronic acid, the filler market also includes calcium hydroxylapatite, poly-L-lactic acid, and polymethylmethacrylate microspheres, each with distinct properties tailored for specific applications.While fillers are well-established in cosmetic practices, their non-cosmetic applications are recently gaining more prominence in otolaryngology...Additionally, autologous fat grafting, as a potentially more permanent alternative, will be addressed. Panelists will also examine the potential risks associated with these products and discuss best practices for complication management.Learning Objectives: Review the development, properties, and regulatory approval of various soft-tissue fillers and their implications for clinical use.Examine the non-aesthetic applications of soft-tissue fillers in..."

Clinical • Aesthetic Medicine • Otorhinolaryngology

Post-Menopause Skin Rejuvenation Study (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Erevna Innovations Inc.

New P4 trial

Effectiveness and Safety of a Cross-Linked Hyaluronic Acid Plus Mannitol Filler for the Correction of Nasolabial Folds in Chinese Subjects: A Randomized, Blinded, Controlled Study. (PubMed, Aesthet Surg J) - "Non-inferiority of the investigational device versus the comparator in correcting NLFs in Chinese subjects was demonstrated. Results up to 12 months suggest comparable safety and effectiveness profiles."

Journal • Aesthetic Medicine

Who's Injecting You? Assessing Provider Credentials Among Manhattan's Aesthetic Injectors (PSTM 2025) - "First, providers were located through the "Find a Provider" feature on the official websites of dermal filler brands, including Bellafill, Juvederm, Radiesse, Restylane, RHA, Belotero, and Sculptra, with search parameters set to Manhattan, New York, and within a 5-mile radius. Our review of the top online results for aesthetic injectors in Manhattan reveals a wide variation in provider qualifications. Although most clinics are physician-owned, a notable number were founded by non-physicians that often lacked on-site doctor or employed non-aesthetic board certified specialists with limited credential transparency. These findings potentiate the need for greater regulatory oversight and consumer education in cosmetic injections."

Aesthetic Medicine • Dermatology • Otorhinolaryngology

The Price of Beauty: Analyzing Medical Malpractice Cases Related to Dermal Fillers (PSTM 2025) - "Silicone was the most frequently cited filler (n=4), followed by Juvederm, Radiesse, Restylane, and Sculptra (all n=3). Medical malpractice cases involving dermal fillers mainly favored defendants. Most defendants were aesthetic specialized physicians, though some lacked medical licenses or board certification in aesthetic specialties. Cases involving unqualified injectors or allegations of battery or fraud had higher odds of plaintiff verdicts or settlements."

Clinical • Aesthetic Medicine • Dermatology • Otorhinolaryngology

Galderma HA Filler Migration (clinicaltrials.gov) - P=N/A | N=10 | Recruiting | Sponsor: Erevna Innovations Inc.

New trial

Pan-Facial Layering of Hyaluronic Acid Filler (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Erevna Innovations Inc.

New trial • Aesthetic Medicine

In Vitro Analysis of Hyaluronidase Degradation of Commercial Hyaluronic Acid Fillers: Considerations in Lip Augmentation. (PubMed, J Craniofac Surg) - "HA fillers vary in their susceptibility to hyaluronidase, likely due to differences in crosslinking and formulation. Fillers with higher degradability, such as Restylane Kysse, may be preferable in high-risk areas or emergency reversal situations. These findings underscore the importance of filler selection in clinical practice and warrant further in vivo studies."

Journal • Preclinical • Aesthetic Medicine • Cardiovascular

A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine (clinicaltrials.gov) - P=N/A | N=171 | Recruiting | Sponsor: Galderma R&D | Not yet recruiting ➔ Recruiting

Enrollment open

A Randomized, Evaluator-blinded, No-treatment Controlled, Multicenter Study of Restylane Skinboosters Vital Lidocaine (clinicaltrials.gov) - P=N/A | N=171 | Not yet recruiting | Sponsor: Galderma R&D

New trial

Alopecia Secondary to Hyaluronic Acid Injection: A Case Report and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "A 23-year-old woman developed a 5×6.5 cm alopecic patch on the left temporal scalp just four days after receiving 5 mL of Restylane hyaluronic acid filler in the frontal area. Knowledge of scalp anatomy and injectable materials is essential. This case suggests that combining Concentrated Growth Factor, microneedling, and minoxidil may offer a promising therapeutic strategy for HA-induced alopecia."

Journal • Review • Aesthetic Medicine • Alopecia • Cardiovascular • Immunology • Inflammation

An epidemiologic assessment of FDA-reported complications of cosmetic injections, 2020-2024 (SID 2025) - "All entries over a 5-year period (1/1/2020 to 12/31/2024) were included for the following brands: Restylane, Juvéderm, and Sculptra...Product rheology and proprietary, brand specific factors are both implicated in adverse outcomes of cosmetic injections, particularly for risk of infection and vascular obstruction. Given that over 2.5 million soft tissue filler injections are performed annually across the United States and this number continues to rise, vigilant epidemiologic assessment is critical to identify risks of branded product lines in order to ensure safety in dermatologic care."

Clinical • Infectious Disease

Vocal Process Granulomas: Insights and Management (COSM 2025) - "Second-line treatments commonly included speech therapy (n=7) and Restylane injections (n=2), while third-line treatments utilized newer approaches such as Voluma injections (n=1), KTP laser (n=1), and fat augmentation (n=1)... Nineteen patients (15 male/4 female, average age 56.74±14.46 ranging from 34-79 years) were identified. Four presented with bilateral VPGs, while the remaining were unilateral. The most common first-line treatments were combination proton pump inhibitors (PPIs) and speech therapy (n=9), followed by inhaled corticosteroids (ICS) alone (n=8)."

Restylane Vocal Fold Augmentation: Assessing Safety and Duration of Efficacy (COSM 2025) - "Restylane is a safe and effective treatment for glottic insufficiency. Average benefit duration lasts 170 days, and many patients may experience ongoing benefits beyond."

Clinical • Gastrointestinal Disorder

Safety and Effectiveness of Restylane® Kysse for Lip Augmentation in Chinese Subjects (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Galderma R&D | Active, not recruiting ➔ Completed

Trial completion

Effect of Recombinant Human Hyaluronidase on Conventional Hyaluronic Acid Fillers: An In Vitro Analysis. (PubMed, J Drugs Dermatol) - "This study demonstrates the in vitro response of different HA fillers to hyaluronidase. Each filler exhibited a variable dose effect. HA concentration (mg/mL) was the critical variable in determining the rate of hydrolysis. Therefore, HA concentration may be an important factor when calculating the dose of hyaluronidase needed to reverse HA fillers. J Drugs Dermatol. 2025;24(3):303-306. doi:10.36849/JDD.8428."

Journal • Preclinical

Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing (clinicaltrials.gov) - P=N/A | N=225 | Completed | Sponsor: Galderma R&D | Active, not recruiting ➔ Completed

Trial completion

Restylane Shaype Versus Juvederm Volux for Chin Augmentation (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Erevna Innovations Inc. | Active, not recruiting ➔ Completed

Trial completion

Comparative in-vitro degradation of hyaluronic acids exposed to different hyaluronidase enzymes. (PubMed, J Oral Biol Craniofac Res) - "Four commercially available HA were used: Lyft (Lt; Restylane, Galderma, Sweden), Voluma (Vol; Allergan, AbbVie, USA), UltraDeep (UDe; Rennova, Innovapharma, Brazil), and Subskin (Skn; Perfectha, Sinclair, France)...Furthermore, differences among HSE formulations do not appear to significantly impact HA degradation, while the mixing movement of HSE and HA seems to influence the degradation rate. These findings may help guide clinical decisions regarding the use of hyaluronidase in managing HA filler complications or adjustments."

Journal • Preclinical

Multimodal Pilot Evaluation of a Hyaluronic Acid Infraorbital Filler Using Precise, Multipositional, 3-Dimensional Imaging Quantification, Patient-Reported Outcomes, and Anatomic Cadaveric Assessments. (PubMed, Aesthet Surg J Open Forum) - "Juvéderm Vycross (Allergan Aesthetics, an AbbVie Company, Irvine, CA) and Restylane NASHA (Galderma, Lausanne, Switzerland) products were injected into the infraorbital and malar region in 6 cephalus specimens and evaluated with regards to the anatomic injection location with and without common clinical physical manipulations...Volbella XC effectively augments undereye volume to diminish infraorbital hollowing as measured over a 90-day period with significantly improved PROs. Enhanced knowledge of the behavior of Volbella XC and other HA fillers in this sensitive anatomic region will lead to improved patient outcomes."

Journal • Patient reported outcomes